Skip to main content
main-content

Spondyloarthropathies

Psoriatic arthritis

17-06-2019 | JAK inhibitors | EULAR 2019 | News

EQUATOR analysis shows patient-level response to filgotinib in PsA

Analysis of the EQUATOR trial has shown that patients treated with the Janus kinase inhibitor filgotinib for active psoriatic arthritis generally achieve a quick response that remains stable over time.

15-06-2019 | Psoriatic arthritis | EULAR 2019 | Article

Expert commentary: The SPIRIT-H2H trial

Laura Coates discusses why the results of the SPIRIT-H2H trial are important for clinical practice (2:41).

15-06-2019 | Psoriatic arthritis | EULAR 2019 | Article

Researcher comment: The SPIRIT-H2H trial

Lead investigator Philip Mease discusses the findings from the SPIRIT-H2H trial, a phase III head-to-head trial of ixekizumab versus adalimumab in patients with psoriatic arthritis (7:15).

15-06-2019 | Psoriatic arthritis | EULAR 2019 | News

Ixekizumab tops adalimumab in head-to-head PsA trial

Findings from the SPIRIT-H2H trial, presented at the EULAR 2019 congress in Madrid, Spain, have demonstrated superior efficacy of ixekizumab versus adalimumab among patients with psoriatic arthritis.

14-06-2019 | Psoriatic arthritis | EULAR 2019 | News

Bimekizumab shows dual efficacy in patients with psoriatic arthritis

Research shows that patients with psoriatic arthritis gain substantial improvements in both musculoskeletal and skin symptoms with bimekizumab, highlighting the benefits of its ability to neutralize both interleukin-17A and 17F.

12-06-2019 | Psoriatic arthritis | EULAR 2019 | News

Tildrakizumab shows promise for PsA

Phase IIb trial results reported at the EULAR 2019 congress in Madrid, Spain, suggest that tildrakizumab may be a promising treatment option for people with psoriatic arthritis.

12-06-2019 | Psoriatic arthritis | EULAR 2019 | Article

Researcher comment: Tildrakizumab shows promise for PsA

Lead investigator Philip Mease outlines the results of a phase IIb trial supporting further development of the anti-interleukin-23p19 monoclonal antibody tildrakizumab for the treatment of psoriatic arthritis (8:45).

10-06-2019 | Psoriatic arthritis | Feature | Article

A closer look at guidelines for the management of PsA

Laura Coates talks to medwireNews about the latest ACR/NPF guidelines for managing psoriatic arthritis, discussing the evidence supporting the recommendations and how they compare with others.

06-06-2019 | Psoriatic arthritis | News

Atherosclerotic plaque burden may aid CV risk prediction in psoriatic disease

Increased atherosclerotic plaque burden, as estimated by carotid ultrasound, is associated with an increased risk for cardiovascular events in patients with psoriatic disease, Canadian researchers report.

22-05-2019 | Psoriatic arthritis | News

Comorbidities linked to worse physical function in psoriatic arthritis patients

Psoriatic arthritis patients with multiple comorbidities have worse physical function than those with just one comorbidity, according to a cross-sectional analysis of the CARMA study of patients from daily clinical practice in Spain.

16-05-2019 | Psoriatic arthritis | News

Insights given into TNFi treatment patterns for patients with PsA

Patients initiating their first tumor necrosis factor inhibitor for psoriatic arthritis have a longer time to discontinuation and are less likely to switch treatment than those previously treated with a drug from the same class, say researchers.

15-05-2019 | Secukinumab | News

Pooled analysis demonstrates favorable long-term safety profile of secukinumab

Analysis of data from 21 randomized controlled trials indicates that the interleukin-17A inhibitor secukinumab has a favorable long-term safety profile among patients with psoriatic arthritis, ankylosing spondylitis, or psoriasis.

29-04-2019 | Etanercept biosimilar | News

FDA approves etanercept biosimilar

Click through for more information on this announcement

08-04-2019 | Biomarkers | Highlight | News

Biomarker panel may help differentiate PsA from osteoarthritis

A panel of four soluble biomarkers comprising markers of cartilage metabolism, metabolic syndrome, and inflammation could distinguish psoriatic arthritis from osteoarthritis, researchers report.

Biomarker panel may help differentiate PsA from osteoarthritis

A panel of four soluble biomarkers comprising markers of cartilage metabolism, metabolic syndrome, and inflammation could distinguish psoriatic arthritis from osteoarthritis, researchers report.

06-03-2019 | Psoriatic arthritis | News

Early TNF inhibitor initiation benefits patients with psoriatic arthritis

Initiating the tumor necrosis factor inhibitor golimumab at the same time as methotrexate almost doubles the rate of remission versus methotrexate monotherapy in patients with early psoriatic arthritis, study findings indicate.

Immunogenicity of influenza vaccine confirmed in patients with rheumatic disease

Influenza vaccination gives rise to an adequate immune response among patients with rheumatic conditions, researchers report.

Image Credits